abstract |
A potent serine protease inhibitor capable of inhibiting Factor Xa, Factor XIIa, plasma kallikrein, and human leukocyte elastase is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor Xa, Factor XIIa, plasma kallikrein, or HLE is indicated. |